[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., vol. 68, no. 6, pp. 394–424, Nov. 2018.
[2] M. Schena, D. Shalon, R. W. Davis, and P. O. Brown, “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray,” Science (80-. )., vol. 270, no. 5235, pp. 467–470, Oct. 1995.
[3] H. J. Chang et al., “Rapid diagnosis of tuberculosis directly from clinical specimens using a gene chip,” Clin. Microbiol. Infect., vol. 16, no. 8, pp. 1090–1096, Aug. 2010.
[4] L. Pongor, M. Kormos, C. Hatzis, L. Pusztai, A. Szabó, and B. Győrffy, “A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients,” Genome Med., vol. 7, no. 1, p. 104, Dec. 2015.
[5] D. P. Bartel, “MicroRNAs: Target Recognition and Regulatory Functions,” Cell, vol. 136, no. 2, pp. 215–233, Jan. 2009.
[6] E. Zonari et al., “A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice,” Blood, vol. 122, no. 2, pp. 243–252, Jul. 2013.
[7] I. A. Vinnikov et al., “Hypothalamic miR-103 Protects from Hyperphagic Obesity in Mice,” J. Neurosci., vol. 34, no. 32, pp. 10659–10674, Aug. 2014.
[8] S. B. Eichmüller, W. Osen, O. Mandelboim, and B. Seliger, “Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape,” JNCI J. Natl. Cancer Inst., vol. 109, no. 10, Oct. 2017.
[9] C.-J. Wang et al., “The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs,” Mol. Cancer, vol. 18, no. 1, p. 115, Dec. 2019.
[10] A. Jacobsen, J. Silber, G. Harinath, J. T. Huse, N. Schultz, and C. Sander, “Analysis of microRNA-target interactions across diverse cancer types,” Nat. Struct. Mol. Biol., vol. 20, no. 11, pp. 1325–1332, Nov. 2013.
[11] M. E. Hatley et al., “Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21,” Cancer Cell, vol. 18, no. 3, pp. 282–293, Sep. 2010.
[12] M. Garofalo et al., “miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation,” Cancer Cell, vol. 16, no. 6, pp. 498–509, Dec. 2009.
[13] T. Barrett et al., “NCBI GEO: archive for functional genomics data sets—update,” Nucleic Acids Res., vol. 41, no. D1, pp. D991–D995, Nov. 2012.
[14] H. Dweep and N. Gretz, “miRWalk2.0: a comprehensive atlas of microRNA-target interactions,” Nat. Methods, vol. 12, no. 8, pp. 697–697, Aug. 2015.
[15] P. Shannon, “Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks,” Genome Res., vol. 13, no. 11, pp. 2498–2504, Nov. 2003.
[16] Y. Zhou et al., “Metascape provides a biologist-oriented resource for the analysis of systems-level datasets,” Nat. Commun., vol. 10, no. 1, p. 1523, Dec. 2019.
[17] D. Szklarczyk et al., “STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Res., vol. 47, no. D1, pp. D607–D613, Jan. 2019.
[18] D. S. Chandrashekar et al., “UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses,” Neoplasia, vol. 19, no. 8, pp. 649–658, Aug. 2017.
[19] B. Győrffy, P. Surowiak, J. Budczies, and A. Lánczky, “Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer,” PLoS One, vol. 8, no. 12, p. e82241, Dec. 2013.
[20] Á. Nagy, A. Lánczky, O. Menyhárt, and B. Győrffy, “Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets,” Sci. Rep., vol. 8, no. 1, p. 9227, Dec. 2018.
[21] F. Wang, Z. Wang, X. Gu, and J. Cui, “miR-940 Upregulation Suppresses Cell Proliferation and Induces Apoptosis by Targeting PKC-δ in Ovarian Cancer OVCAR3 Cells,” Oncol. Res. Featur. Preclin. Clin. Cancer Ther., vol. 25, no. 1, pp. 107–114, Jan. 2017.
[22] S. Rajendiran, A. V Parwani, R. J. Hare, S. Dasgupta, R. K. Roby, and J. K. Vishwanatha, “MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1,” Mol. Cancer, vol. 13, no. 1, p. 250, 2014.
[23] J. Ma et al., “Depletion of intermediate filament protein Nestin, a target of microRNA-940, suppresses tumorigenesis by inducing spontaneous DNA damage accumulation in human nasopharyngeal carcinoma,” Cell Death Dis., vol. 5, no. 8, pp. e1377–e1377, Aug. 2014.
[24] B. Yuan, Y. Liang, D. Wang, and F. Luo, “MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients,” Cancer Sci., vol. 106, no. 7, pp. 819–824, Jul. 2015.
[25] Y. Fan et al., “MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of prograMMEd death ligand-1 expression,” Exp. Cell Res., vol. 373, no. 1–2, pp. 180–187, Dec. 2018.
[26] R. Wang, Y. Wu, W. Huang, and W. Chen, “MicroRNA-940 Targets INPP4A or GSK3β and Activates the Wnt/β-Catenin Pathway to Regulate the Malignant Behavior of Bladder Cancer Cells,” Oncol. Res. Featur. Preclin. Clin. Cancer Ther., vol. 26, no. 1, pp. 145–155, Jan. 2018.
[27] B. Song, C. Zhang, G. Li, G. Jin, and C. Liu, “MiR-940 Inhibited Pancreatic Ductal Adenocarcinoma Growth by Targeting MyD88,” Cell. Physiol. Biochem., vol. 35, no. 3, pp. 1167–1177, 2015.
[28] K. C. Kim et al., “Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1,” Theranostics, vol. 8, no. 16, pp. 4409–4428, 2018.
[29] L. Hou et al., “MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer,” Oncol. Lett., vol. 14, no. 4, pp. 4441–4448, Oct. 2017.
[30] W. Dong, C. Yao, X. TENG, J. Chai, X. Yang, and B. Li, “MiR-140-3p suppressed cell growth and invasion by downregulating the expression of ATP8A1 in non-small cell lung cancer,” Tumor Biol., vol. 37, no. 3, pp. 2973–2985, Mar. 2016.
[31] T. Sun, Y. Song, H. Yu, and X. Luo, “Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis’s proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis,” Cancer Biol. Ther., vol. 20, no. 6, pp. 760–773, Jun. 2019.
[32] I. Bray et al., “MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma,” Cancer Lett., vol. 303, no. 1, pp. 56–64, Apr. 2011.
[33] M. Zhou et al., “A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells,” Cancer Res., vol. 73, no. 23, pp. 7056–7067, Dec. 2013.